Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies.

BMJ Open Diabetes Res Care · 2020 · PMC7371226 · PMID 32690574

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Discussion Meta-analysis of economic studies suggests that GLP1s are significantly more cost-effective compared with insulin in HICs but not in UMICs ( figure 4 ); point estimates versus other antidiabetic agents, including DPP4i, sulfonylureas, and thiazolidines, also favour GLP-1, but these did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.